DRNA News
Archived Headlines
- Renaissance Capital's 1Q 2014 US IPO Quarterly Review 04/01/14
- US IPO Recap: Varonis provides data security for enterprises and financial security for investors 03/03/14
- US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs 02/03/14
- Dicerna gains 207% in market debut, best biotech first-day pop since 2000 01/30/14
- Dicerna Pharmaceuticals prices IPO at $15, above the upwardly revised range 01/29/14
See more
More capital for Canadian cancer cures: ProNAi Therapeutics increases proposed IPO deal size by 37%
ProNAi Therapeutics, which is developing cancer therapies based on DNA interference, raised the proposed deal size for its upcoming IPO on Wednesday. The Vancouver, Canada-based company now plans to raise $138 million by offering 8.1 million shares at a...read more
Canadian cancer biotech ProNAi Therapeutics sets terms for $101 million IPO
ProNAi Therapeutics, which is developing cancer therapies based on DNA interference, announced terms for its IPO on Monday. The Vancouver, Canada-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the...read more
Something good out of Canada: Cancer biotech ProNAi Therapeutics files for an $86 million IPO
ProNAi Therapeutics, which is developing cancer therapies based on DNA interference, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Vancouver, Canada-based company, which was founded in 2003, plans to list on the...read more
The harder they fall: high-popping IPOs hammered in aftermarket trading
As the NASDAQ experienced its biggest one-day drop since late 2011 amid a continued tech sell-off, the biggest losers have been companies that saw spectacular first-day trading. The market's downturn is a response to some speculative buying of these as-of-yet...read more